share_log

Impressive Earnings May Not Tell The Whole Story For Shenzhen Kangtai Biological Products (SZSE:300601)

Impressive Earnings May Not Tell The Whole Story For Shenzhen Kangtai Biological Products (SZSE:300601)

令人印象深刻的收益可能无法说明深圳康泰生物制品(SZSE: 300601)的全部情况
Simply Wall St ·  05/03 19:23

Unsurprisingly, Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing some concerning details in the numbers.

不出所料,深圳康泰生物制品有限公司's(深圳证券交易所股票代码:300601)的股价因其健康的收益报告而表现强劲。但是,我们认为股东们可能遗漏了一些与数字相关的细节。

earnings-and-revenue-history
SZSE:300601 Earnings and Revenue History May 3rd 2024
SZSE: 300601 收益和收入历史记录 2024 年 5 月 3 日

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

To properly understand Shenzhen Kangtai Biological Products' profit results, we need to consider the CN¥215m gain attributed to unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. We can see that Shenzhen Kangtai Biological Products' positive unusual items were quite significant relative to its profit in the year to March 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

为了正确了解深圳康泰生物制品的盈利业绩,我们需要考虑不寻常项目带来的2.15亿元人民币的收益。虽然我们希望看到利润增加,但当不寻常的物品做出重大贡献时,我们往往会更加谨慎一些。当我们计算数千家上市公司的数字时,我们发现,特定年份中不寻常的项目所带来的提振通常不会在第二年重演。考虑到这个名字,这并不奇怪。我们可以看到,截至2024年3月的一年中,深圳康泰生物制品的正面不寻常项目与其利润相比相当可观。在其他条件相同的情况下,这可能会使法定利润成为衡量潜在盈利能力的不良指导。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

Our Take On Shenzhen Kangtai Biological Products' Profit Performance

我们对深圳康泰生物制品盈利表现的看法

As we discussed above, we think the significant positive unusual item makes Shenzhen Kangtai Biological Products' earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Shenzhen Kangtai Biological Products' underlying earnings power is lower than its statutory profit. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. For example, we've discovered 2 warning signs that you should run your eye over to get a better picture of Shenzhen Kangtai Biological Products.

正如我们上面讨论的那样,我们认为这一重大利好不寻常的项目使深圳康泰生物制品的收益无法衡量其潜在盈利能力。因此,我们认为深圳康泰生物制品的潜在盈利能力很可能低于其法定利润。好的一面是,该公司在去年亏损之后,表现出了足够的改善,今年实现了盈利。当然,我们只是在分析其收益时才浮出水面;人们还可以考虑利润率、预测增长和投资回报率等因素。请记住,在分析股票时,值得注意所涉及的风险。例如,我们发现了两个警告标志,为了更好地了解深圳康泰生物制品,你应该仔细检查一下。

Today we've zoomed in on a single data point to better understand the nature of Shenzhen Kangtai Biological Products' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我们放大了单一数据点,以更好地了解深圳康泰生物制品利润的性质。但是,如果你能够将注意力集中在细节上,总会有更多的事情需要发现。有些人认为高股本回报率是优质业务的好兆头。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发